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with radiation and TMZ. We also confirmed the 
radiosensitizing effect of Cpd188 of GBL28 cell which was 
originated from a patient with high level of STAT3 expression 
and unmethylated MGMT. 
 
Conclusion: Targeting STAT3 using Cpd188 could be a viable 
therapeutic approach to improve the outcome of current 
standard therapy for glioblastoma patients having high p-
STAT3 expression regardless of MGMT methylation status. 
Work supported by the grant (#2013R1A1A2074531) from the 
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Purpose or Objective: Purpose: Stress responses in cancer 
cells are exaggerated over that of normal tissues include 
signal transduction pathways such as GRP78, PKC, PLC, Rho 
and others. Many of these regulators of cell viability 
translocate of the cell membrane during the stress response. 
Mechanisms of protein transport include motor and scaffold 
proteins such as Tax Interacting protein-1 (TIP-1), which 
translocates to the surface of the cell membrane of cancer 
cells following exposure to ionizing radiation. TIP1 is a 
scaffold protein that moves proteins to and from the cell 
membrane. It is over expressed in poor prognosis cancers.  
 
Material and Methods: Methods: We studied radiation 
induction of TIP1 by western immunoblot and flow 
cytometry. We used siRNA to knock down TIP1 in human GBM 
and NSCLC cell lines. We utilized Anti-TIP1 antibodies 
administered IV to mouse models of human cancer 
xenografts. We measured tumor growth delay. To assess the 
ability of mouse NK cells to target and kill anti-TIP1 antibody-
opsonized lung cancers, we cultured H460, or LLC cells in 96-
well plates at 37oC. After 40 hr., cells were irradiated with 3 
Gy (or shield) to induce TIP1 expression. Cells were 
continued in culture for 4 hr. 10 ug/ml 2C6F3, NMIgG, or 
media were added and incubated for an additional 2 hr. 
Murine NK cells were added and Incubated for 16 hr. 
Cytotoxicity was then determined by cancer cells cytolysis. 
anti-TIP1 antibodies (Ab) that bind to the PDZ domain of this 
protein were administered IV to mice bearing irradiated 
human cancers. 
 
Results: Results: Membrane protein western blots showed a 
significant increase in the expression of TIP-1 protein at 4 
and 24 hrs following irradiation with 3 Gy as compared to 0 
Gy untreated control tumors. Significant levels of the TIP-1 
membrane protein were also present in the irradiated 
tumors, but not in untreated controls, as demonstrated by 
immunohistochemistry. Near-infrared imaging studies showed 
significant targeting and binding of anti-TIP-1 Ab to 
irradiated tumors compared to untreated tumors and IgG 
controls at 72 hrs. Knockdown of TIP1 and blocking Abs that 
bind to the PDZ domain of TIP1 enhance cytotoxicity in 
cancer but not normal tissues. Anti-PDZ-domain Abs 
significantly enhanced cytotoxicity in D54, H1299, H460 and 
A549 human cancer cells. We studied the mechanisms by 
which the Abs enhance cytotoxity and improve tumor control. 
Abs activate caspases 2, 3/7 in irradiated cancers. Moreover, 
Anti-TIP1 antibodies bound to the surface of cancer cells 
activated immune effector cells. In mouse models of human 
cancers, Anti- TIP1 Abs enhanced tumor growth delay after 
radiotherapy when administered IV to mouse models of 
human cancer. 
 
Conclusion: Conclusion: Anti- TIP1 antibodies activate 
immune effector cells and enhance the efficacy of 
radiotherapy specifically in cancer without enhancing the 
response in normal tissues. TIP1 is a molecular target for the 
development of novel radiation sensitizing agents. 
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Purpose or Objective: YB-1, a protein increasingly 
associated with tumour progression and treatment resistance 
in prostate cancer, is the only known ligand of the Notch-3 
receptor. The Notch pathway is an evolutionarily conserved 
signaling system whose inhibition is under scrutiny as a novel 
therapeutic approach. We have previously identified elevated 
Notch-3 mRNA expression in high grade prostate cancer. This 
study investigated the anti-tumour properties of the YB-1 
inhibitor Fisetin, a dietary flavonoid, in an isogenic model of 
radioresistant prostate cancer cells in vitro.  
 
Material and Methods: An isogenic model of radioresistance 
was generated in 22Rv1 prostate cancer cells through 
exposure to 30 x 2-Gy dose fractions. YB-1 and Notch-3 
expression were determined by western blotting in parent, 
aged-matched and radioresistant cells following irradiation 
(5Gy) and/or 60uM Fisetin treatment (24hrs). Patterns of 
expression were related to modification in cell cycle 
distribution through analysis of PI staining by flow cytometry 
and clonogenic survival. The anti-tumour effects of fisetin 
were compared to those of two notch inhibitors DAPT and 
Batimastat.  
 
Results: Following a cumulative total dose of 60Gy, the 
resulting subline RR22Rv1 was associated with a significant 
increase in clonogenic survival (1.3 fold increase in survival 
after 2Gy and 2.2 fold increase after 10Gy) when compared 
to both parent 22Rv1 and aged-matched controls. YB-1 was 
detected in the cytoplasm of all three lines. Expression levels 
were elevated following irradiation (4Gy) in RR22Rv1. 
Radiation (5Gy) inhibited activation and nuclear translocation 
of Notch-3. Fisetin treatment led to a loss of Notch-3 
cytoplasmic expression in RR22Rv1 cells. DAPT and 
Batimastat did not affect clonogenic survival of 22RV1 and 
RR22Rv1 cells. Fisetin induced G2 cell cycle arrest and 
significantly reduced clonogenic survival in untreated and 5-
Gy irradiated parent and RR22Rv1 cells.  
 
Conclusion: This study identifies potential role of the YB-1-
Notch-3 interaction in the radioresistance of prostate cancer 
cells, and highlights fisetin as a novel therapeutic agent for 
the management of prostate cancer.  
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Purpose or Objective: More than 50% all cancer patients 
receive radiation therapy. Despite recent innovations, 
clinical delivery of curative radiation doses is strictly 
restricted by the proximal healthy tissues. Chemical/ 
biological agents to augment the radiosensitization of cancer 
cells are limited by severe off-target toxicity concerns. We 
propose a dual-targeting strategy using tumor vascular-
targeted gold nanoparticles (which amplify 
radiosensitization) combined with the conformal image-
guided radiation therapy to induce tumor vascular disruption. 
This is a unique concept with a clear translational path. 
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Material and Methods: Chemically synthesized, RGD-/PEG- 
functionalized gold nanoparticles (RGD:AuNP; ≈2 -3 nm) were 
characterized using STEM, TEM, and LIBS imaging. Following 
clonogenic assay, radiation damage was induced in Panc1 
xenografts with 10 Gy and 220 kVp (Xtrahl, Inc). γ-H2AX, 3D-
(confocal) vessel imaging and IHC were performed. 
 
Results: Tumor vessel-targeted gold nanoparticles were 
subjected to conformal image-guided irradiation in Panc-1 
tumor xenograft to induce tumor vascular disruption. By 
specifically targeting the early angiogenic tumor 
endothelium, RGD:AuNP circumvent the dense stromal 
diffusion pathways that often limits the penetration and 
permeation of anti-cancer drugs/ nanoparticles to the cancer 
cells - a limitation of current radiosensitization approaches. 
In vitro testing in HUVEC displayed ≥3 -fold difference 
(***P<0.0001) in radiation damage in the +RGD:AuNP/+IR 
compared to the controls. More to it, the sub-millimeter 
accuracy of image-guided radiation therapy facilitated 
improved therapeutic efficacy (95%-100% tumor dose 
distribution) and less off-target toxicities. Quantification of 
the DNA-strand breaks (by γH2AX) showed ≈3 -fold increase 
(P<0.001) in the radiation specific DNA damage in the 
'nanoparticle-radiation' cohort (+RGD:AuNP/+IR: 57%) 
compared to the 'radiation' group (−RGD:AuNP/+IR:19%) and 
almost ≈10 -fold difference (P<0.001) compared to 
(+RGD:AuNP/−IR: 6% and −RGD:AuNP/−IR: 6%). 
 
Conclusion: This dual-targeting strategy holds great 
translational potential in radiation oncology. The resulting 
vascular disruption substantially improved the therapeutic 
outcome and subsidized the radiation/ nanoparticle toxicity, 
extending its utility to intransigent/ non-resectable tumors 
that barely respond to standard therapies. This abstract 
presents the first in-depth experimental investigation of 
tumor vascular disruption with nanoparticles, a novel 
strategy in radiation therapy. 
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Purpose or Objective: Inhibition of checkpoint kinases Wee1 
or Chk1 causes G2-checkpoint abrogation and mitotic 
catastrophe, particularly in p53 defective tumors. Based on 
this, Wee1 and Chk1 inhibitors are currently in clinical trials, 
combined with radiation or chemo-therapy. However, our 
previous work has shown that inhibition of Wee1 or Chk1 also 
causes DNA breakage in S-phase, largely due to high Cyclin-
Dependent-Kinase (CDK)-activity followed by unscheduled 
replication initiation. Furthermore, recent work by others has 
shown synergistic anti-cancer effects after combined Wee1 
and Chk1 inhibition. The aim of this study was to investigate 
whether S-phase DNA damage may contribute to the 
synergistic effects after combined Chk1/Wee1 inhibition. 
 
Material and Methods: Osteosarcoma U2OS and lung cancer 
A549, H460 and H1975 cells were exposed to the Wee1 
inhibitor MK1775 and/or the Chk1 inhibitors AZD7762, 
LY2606368, MK8776 and UCN01. The DNA damage marker 
gH2AX was analyzed in S-phase cells by flow cytometry. DNA 
damage signaling and inhibitory phosphorylation of CDK1 and 
CDK2 were examined by immunoblotting, and cell survival by 
clonogenic survival assays. CDK activity was measured in S-
phase cells by a novel flow cytometry barcoding method. In 
this method, CDK-dependent phosphorylations (antibodies to 
phospho-BRCA2 S3291, phospho-bMyb T487 and phospho-
Mpm2) versus DNA content (Hoechst staining) were examined 
in individual cells. Barcoding with Pacific Blue was included 
to reduce sample-to-sample variations. Loading of the 
replication initiation factor CDC45 was measured by a similar 
flow cytometry method and by immunoblotting after removal 
of unbound proteins by extraction with salt and detergent. 
 
Results: We observed a strong synergy in induction of S-phase 
damage after combined Wee1 and Chk1 inhibition. Also, 
clonogenic survival was strongly decreased after the 
combined treatment. Surprisingly, this synergy could not be 
explained by increased CDK-activity, as S-phase CDK-activity 
did not correlate with induction of DNA damage after Wee1 
and Chk1 inhibition. Wee1 inhibition caused a bigger increase 
in CDK-activity than Chk1 inhibition. However, Chk1 
inhibition caused more S-phase damage and loading of the 
replication factor CDC45. The combination of Wee1 and Chk1 
inhibitors further increased the CDC45 loading, and the 
extent of CDC45 loading correlated with DNA damage 
induction. 
 
Conclusion: We have shown for the first time that combined 
Wee1 and Chk1 inhibition causes synergistic S-phase DNA 
damage, due to distinct effects of Wee1 and Chk1 kinases in 
regulation of CDK activity and CDC45 loading, respectively. 
This synergy can explain the synergistic anti-cancer effects 
obtained by simultaneous Chk1/Wee1 inhibition. We propose 
that combined Chk1/Wee1 inhibition may be useful together 
with radiation therapy to eliminate radioresistant S-phase 
cells. 
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Purpose or Objective: Purpose: Glioblastoma demonstrates 
progression of disease within the high dose region of 
radiotherapy, in nearly all cases. The physiologic response 
within glioblastoma to radiation is in part dependent upon a 
pro-survival signaling. GRP78 was first described to regulate 
cellular stresses, including hypoglycemia, hypoxia and the ER 
stress response. GRP78 is an important regulator of cell 
stress, and binds to several pro-survival proteins. Antagonists 
to GRP78 include Kringle-5 and PAR4 which induce apoptosis 
in tumor vasculature endothelium and cancer cells. The 
molecular events that result from the ER stress response can 
enhance cell viability. GRP78 is overexpressed in poor 
prognosis cancers and is a molecular therapeutic target in 
poorly differentiated cancers. 
 
Material and Methods: Methods: We studied radiation 
induction of GRP78 by western immunoblot and flow 
cytometry. We used siRNA to knock down GRP78 in human 
GBM and NSCLC cell lines. In order to study the potential 
relationship between radiation dose and induction of ATF6 
activity, we treated D54 cells with 3 Gy and 6 Gy and 
analyzed GRP78 protein expression 48h after irradiation. We 
utilized Anti-GRP78 antibodies administered IV to mouse 
models of human cancer xenografts. We measured tumor 
growth delay using subcutaneous implants of human cancer 
xenografts. 
 
Results: Results: We found that radiation induces the 
expression of GRP78 in glioblastoma. Antibodies to GRP78 
enhanced radiation-induced cytotoxicity in glioblastoma but 
not normal cells. We found that radiation induced GRP78 
expression is regulated through the ER stress response, and 
that ATF6 is responsible for the transcriptional induction of 
GRP78. Knockdown of ATF6 abrogates GRP78 induction and 
enhanced cytotoxicity from radiation. Moreover interruption 
of GRP78 signaling enhances therapeutic effects of radiation. 
GRP78 antibodies enhanced cytotoxicity from radiation in 
human glioblastoma and NSCLC cell lines. We found that the 
levels of GRP78 protein were elevated at the 48 and 72h time 
points. Knockdown of ATF6 was sufficient to abrogate GRP78 
induction. We observed dose dependent increases in GRP78 
levels, which were reproducible when the experiment was 
repeated with LN827 cells. Similar changes were observed in 
GRP78 mRNA levels 48h after IR, where a 75% and 100% 
increase was observed in D54. Anti-GRP-78 antibodies bind 
specifically to irradiated cancers enhanced the efficacy of 
